CMECNE

This activity is supported by educational grants from Forest Laboratories, Inc. and Lilly USA, LLC.

Major Depressive Disorder Summit 2013: Meeting Highlights

CME/CNE Information

Release Date: November 2, 2013

Expiration Date: November 1, 2014

Number of Credits: 2.0

Provider:

Sponsorship Statement: This continuing medical education enduring internet activity is sponsored by Center for Continuing and Outreach Education at Rutgers Biomedical and Health Sciences. 

Educational Partner: This activity was developed in collaboration with Vindico Medical Education.

Support Statement: This activity is supported by educational grants from Forest Laboratories, Inc. and Lilly USA, LLC.

Target Audience: The intended audience for this activity is psychiatrists and psychiatric nurses, and other health care professionals involved in the treatment of patients with major depressive disorder.

Learning Objectives:
Upon completion of this CME activity, participants should be able to:

  1. Incorporate antidepressant switching and augmentation strategies to enhance treatment response rates and achieve remission.
  2. Differentiate non-pharmacologic therapies for major depressive disorder and incorporate them as needed to augment other therapeutic regimens.
  3. Examine the safety, efficacy, and tolerability of current agents and assess new, novel, and investigational agents for the treatment of major depressive disorder.

Upon completion of this CNE activity, participants should be able to:

  1. Assess antidepressant switching strategies that enhance treatment response rates and achieve remission.
  2. Differentiate non-pharmacologic therapies for major depressive disorder and evaluate their ability to augment other therapeutic regimens.
  3. Examine the safety, efficacy, and tolerability of current agents and assess new, novel, and investigational agents for the treatment of major depressive disorder.

Faculty and Planning Committee:
Michael E. Thase, MD – Course Chair
Professor of Psychiatry
Perelman School of Medicine
at the University of Pennsylvania
Philadelphia Veterans Affairs Medical Center
Philadelphia, PA

Marna S. Barrett, PhD*
Research Projects Manager
Adjunct Associate Professor of Psychology in Psychiatry
University of Pennsylvania Perelman School of Medicine
Department of Psychiatry
Mood and Anxiety Disorders Treatment Research Center
Philadelphia, PA

John P. O'Reardon, MD*
Professor and Chair
Department of Psychiatry
Director of the Center for Mood Disorders and Neuromodulation Therapies
Rowan University School of Osteopathic Medicine
Cherry Hill, NJ **

Gerard Sanacora, MD, PhD
Professor of Psychiatry
Yale University School of Medicine
Director of Yale Depression Research Program
New Haven, CT

Thomas L. Schwartz, MD*
Professor
Director of Adult Clinical Services
Director of Medical Student Education
Department of Psychiatry
SUNY Upstate Medical University
Syracuse, NY

Denise Vanacore, PhD, CRNP, ANP-BC, PMHNP
Associate Professor of Nursing
Coordinator, Nurse Practitioner Program
Director, Primary Care and Behavioral Health Services
Gwynedd Mercy College
Gwynedd Valley, PA

*Faculty member’s presentation(s) included in this activity

**At the time of the live presentation on June 29, 2013, Dr. O'Reardon's affiliation included University of Medicine and Denistry of New Jersey School of Osteopathic Medicine. Slides and audio within may reflect his former affiliation.

Peer Reviewer:
Kenneth R. Kaufman, MD, MRCPsych
Professor of Psychiatry, Neurology, and Anesthesiology
Rutgers Robert Wood Johnson Medical School
Piscataway, NJ

Nurse Planners:
Denise Vanacore, PhD, CRNP, ANP-BC, PMHNP
Associate Professor of Nursing
Coordinator, Nurse Practitioner Program
Director, Primary Care and Behavioral Health Services
Gwynedd Mercy College
Gwynedd Valley, PA

Margaret Evans, MSN, RN
Nurse Manager, Education and Performance Improvement
Rutgers Robert Wood Johnson Medical Group
New Brunswick, NJ

Accreditation and Credit Designation:
Rutgers, The State University of New Jersey is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Rutgers, The State University of New Jersey designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Rutgers, The State University of New Jersey, Center for Continuing and Outreach Education is an approved provider of continuing nursing education by the New Jersey State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission On Accreditation. Provider Number P173-12/12-15.

This activity is awarded 2.0 contact hours. (60 minute CH)

Nurses should only claim those contact hours actually spent participating in the activity.

The estimated time to complete this activity is 2 hours.

Approved provider status refers only to continuing education activities and does not imply ANCC COA or NJSNA endorsement of any commercial products.

This activity was pilot-tested for time required for participation by Kathleen Cherwinski, RN, WHNP-BC, MPH, CIC, Sharon Eaton, MSN, RN, Ann Hirschman, RN-C, FNP, MPH, and Aphrodite Zimmerman, MD, MS.

How To Participate in this Activity and Obtain CE Credit:
To participate in this CE activity, you must read the objectives, answer the pretest questions, view the webcasts, complete the CE posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 5 out of 6 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, a CE Certificate will be instantly issued.

Disclosures:
In accordance with the disclosure policies of Rutgers and to conform with ACCME and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.

Planning Committee and Faculty:
Michael E. Thase, MD
Advisory/Consultant: Alkermes; AstraZeneca; Bristol-Myers Squibb Company; Eli Lilly & Co.; Dey Pharma, L.P.; Forest Laboratories (including PGx); Gerson Lehman Group; GlaxoSmithKline; Guidepoint Global; H. Lundbeck A/S; MedAvante, Inc.; Merck and Co. Inc. (including Schering Plough and Organon); Neuronetics, Inc.; Ortho-McNeil Pharmaceuticals (including Johnson & Johnson); Otsuka; Pamlab, L.L.C.; Pfizer (including Wyeth-Ayerst Pharmaceuticals); Roche; Shire US Inc.; Sunovion Pharmaceuticals, Inc.; Takeda; Transcept Pharmaceuticals
Grant Support: Agency for Healthcare Research and Quality; Eli Lilly and Company; Forest Pharmaceuticals; GlaxoSmithKline (ended 7/10); National Institute of Mental Health; Otsuka Pharmaceuticals; Sepracor, Inc. (ended 1/09)
Honoraria for Talks: AstraZeneca; Bristol-Myers Squibb Company; Eli Lilly & Co.; Merck and Co. Inc.; Pfizer (including Wyeth-Ayerst Pharmaceuticals)
Equity Holdings: MedAvante, Inc.
Royalties: American Psychiatric Foundation; Guilford Publications; Herald House; W.W. Norton & Company, Inc.
Spouse’s Employment: Peloton Advantage (Formerly Advogent and Embryon), does business with Pfizer/Wyeth

Marna S. Barrett, PhD
No relevant financial relationships to disclose.

John P. O'Reardon, MD
Grant/Research Support: NeoSync Inc.

Gerard Sanacora, MD, PhD
Grant/Research Support: AstraZeneca; Bristol-Myers Squibb; Eli Lilly & Co.; Hoffmann La-Roche; Merck & Co., Inc; Naurex
Consultant: AstraZeneca; Bristol-Myers Squibb; Eli Lilly & Co.; Hoffmann La-Roche; Naurex; Novartis; Noven Pharmaceuticals
Other: Co-inventor on filed patent application by Yale University (PCTWO06108055A1)

Thomas L. Schwartz, MD
Grant/Research Support: Cyberonics; Teva
Consultant: Pamlab; Mylan
Medical Educator: NEI; Medscape; WebMD
Royalties: Cambridge University; Informa; Routledge Presses

Denise Vanacore, PhD, CRNP, ANP-BC, PMHNP
No relevant financial relationships to disclose.

Peer Reviewer:
Kenneth R. Kaufman, MD, MRCPsych
No relevant financial relationships to disclose.

Nurse Planners:
Denise Vanacore, PhD, CRNP, ANP-BC, PMHNP
No relevant financial relationships to disclose.

Margaret Evans, MSN, RN
No relevant financial relationships to disclose.

Field Testers:
Kathleen Cherwinski, RN, WHNP-BC, MPH, CIC
No relevant financial relationships to disclose.

Sharon Eaton, MSN, RN
No relevant financial relationships to disclose.

Ann Hirschman, RN-C, FNP, MPH
No relevant financial relationships to disclose. 

Aphrodite Zimmerman, MD, MS
No relevant financial relationships to disclose. 

Rutgers Staff Member
Patrick Dwyer – Director, Continuing Medical Education
No relevant financial relationships to disclose.

Vindico Medical Education Staff Members
Ronald Codario, MD, FACP, CCMEP – Medical Director
No relevant financial relationships to disclose.

Bridget Kocher – Vice President, Educational Services
No relevant financial relationships to disclose.

Marykate Nelson, PhD – Senior Medical Writer
No relevant financial relationships to disclose.

Darla Thompson – Program Manager

No relevant financial relationships to disclose.

This activity contains information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved. TMS is not included in the labeling approved by the US FDA where there has been more than one medication failure in the current episode. TMS is not included in the labeling approved by the US FDA for bipolar depression and other neuropsychiatric disorders. Eszopiclone, vortioxetine, lurasidone, s-adenosyl methionine, n-acetyl cysteine, risperidone, asenapine, paliperidone, modafinil, armodafinil, methylphenidate, mixed amphetamine salts, pramipexole, ketamine, DBS, tDCS, are not included in the labeling approved by the US FDA for MDD.

The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of Forest Laboratories, Inc., Lilly USA, LLC, any other manufacturer of pharmaceuticals or devices, Rutgers, or Vindico Medical Education.

It should be noted that the recommendations made herein within regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products or procedures before using them in clinical practice.

Copyright © 2013 Rutgers, The State of New Jersey and Health Sciences and Vindico Medical Education. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from Center for Continuing and Outreach Education at Rutgers.

To review Rutgers’ CME privacy policy, please visit: http://ccoe.rbhs.rutgers.edu/general/privacypolicy.html.

Please direct content or CE related concerns to CCOE at 973-972-4267 or by email at ccoe@ca.rutgers.edu.

Please direct technical questions to Healio.com at 1-800-257-8290 or email webmaster@healio.com.

Hardware and Software Requirements Needed to Participate:

  1. A computer with an Internet connection.
  2. Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser.
  3. Adobe Flash Player and/or an HTML5 capable browser may be required for video or audio playback.
  4. Occasionally other additional software may be required such as PowerPoint or Adobe Acrobat Reader